Iridian Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Iridian Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-935,398	Closed	-$64.9M	–	79
2018 Q3	$64.9M	Buy	935,398 +74,487	+9%	+$5.65M	0.65%	46
2018 Q2	$65.1M	Sell	860,911 -12,220	-1%	-$769K	0.6%	52
2018 Q1	$46M	Sell	873,131 -28,566	-3%	-$1.66M	0.41%	53
2017 Q4	$48.2M	Buy	901,697 +87,483	+11%	+$4.87M	0.41%	53
2017 Q3	$48.6M	Buy	814,214 +119,327	+17%	+$7.22M	0.41%	52
2017 Q2	$54.8M	Sell	694,887 -60,140	-8%	-$4.92M	0.48%	54
2017 Q1	$62.6M	Buy	755,027 +715,382	+1,804%	+$53.2M	0.56%	54
2016 Q4	$3.15M	Buy	39,645 +12,500	+46%	+$908K	0.03%	60
2016 Q3	$1.9M	Buy	27,145 +6,580	+32%	+$365K	0.02%	61
2016 Q2	$798K	Buy	+20,565	New	+$856K	0.01%	62

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Iridian Asset Management's EGRX Position: Q4 2018 in Review

Iridian Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2018, closing a stake of 935,398 shares — an estimated $64.9M sold.

Iridian Asset Management first reported a position in EGRX in Q2 2016 and held it in 10 quarters. The position peaked at $65.1M in Q2 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q4 2018.

Iridian Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Iridian Asset Management sold 935,398 Eagle Pharmaceuticals, Inc. shares in Q4 2018, an estimated $64.9M.
Iridian Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 10 quarters.
Iridian Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $65.1M in Q2 2018.
182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2018.

Based on Iridian Asset Management's 13F filing for Q4 2018, filed 7 Feb 2019.